Goldman Sachs
RPRX icon

Goldman Sachs’s Royalty Pharma RPRX Stock Holding History

Goldman Sachs’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121M Buy
2,522,546
+971,646
+63% +$42.6M 0.01% 919
2025
Q4 		$59.9M Sell
1,550,900
-94,727
-6% -$3.61M 0.01% 1356
2025
Q3 		$58.1M Buy
1,645,627
+1,259,758
+326% +$45.6M 0.01% 1310
2025
Q2 		$13.9M Sell
385,869
-33,365
-8% -$1.11M ﹤0.01% 2457
2025
Q1 		$13.1M Sell
419,234
-146,917
-26% -$4.66M ﹤0.01% 2443
2024
Q4 		$14.4M Buy
566,151
+95,732
+20% +$2.54M ﹤0.01% 2434
2024
Q3 		$13.3M Buy
470,419
+151,237
+47% +$4.19M ﹤0.01% 2442
2024
Q2 		$8.42M Sell
319,182
-283,806
-47% -$7.87M ﹤0.01% 2676
2024
Q1 		$18.3M Sell
602,988
-2,266,558
-79% -$66.8M ﹤0.01% 1916
2023
Q4 		$80.6M Sell
2,869,546
-1,340,649
-32% -$36.8M 0.01% 889
2023
Q3 		$114M Buy
4,210,195
+563,139
+15% +$16.7M 0.02% 653
2023
Q2 		$112M Buy
3,647,056
+1,343,711
+58% +$45.5M 0.02% 660
2023
Q1 		$83M Buy
2,303,345
+1,081,886
+89% +$40.1M 0.02% 778
2022
Q4 		$48.3M Sell
1,221,459
-155,246
-11% -$6.48M 0.01% 1201
2022
Q3 		$55.3M Buy
1,376,705
+390,178
+40% +$16.7M 0.01% 1049
2022
Q2 		$41.5M Sell
986,527
-401,103
-29% -$16.4M 0.01% 1254
2022
Q1 		$54.1M Buy
1,387,630
+82,110
+6% +$3.22M 0.01% 1211
2021
Q4 		$52M Buy
1,305,520
+408,117
+45% +$15.9M 0.01% 1301
2021
Q3 		$32.4M Sell
897,403
-66,698
-7% -$2.59M 0.01% 1631
2021
Q2 		$39.5M Buy
964,101
+571,931
+146% +$24.3M 0.01% 1461
2021
Q1 		$17.1M Sell
392,170
-135,590
-26% -$6.43M ﹤0.01% 2062
2020
Q4 		$26.4M Buy
527,760
+351,857
+200% +$14.9M 0.01% 1626
2020
Q3 		$7.4M Buy
175,903
+145,500
+479% +$6.24M ﹤0.01% 2580
2020
Q2 		$1.48M Buy
+30,403
New +$1.5M ﹤0.01% 3676

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs's RPRX Position: Q1 2026 in Review

Goldman Sachs increased its Royalty Pharma (RPRX) stake by 63% in Q1 2026, buying an estimated $42.6M and bringing the position to 2,522,546 shares worth $121M. The position accounts for 0.01% of the portfolio, ranked #919.

Goldman Sachs first reported a position in RPRX in Q2 2020 and has held it in 24 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Goldman Sachs held 2,522,546 shares of Royalty Pharma worth $121M as of Q1 2026.
  • Goldman Sachs bought 971,646 Royalty Pharma shares in Q1 2026, an estimated $42.6M.
  • Royalty Pharma made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #919 holding.
  • Goldman Sachs first reported a position in Royalty Pharma in Q2 2020 and has held it in 24 quarters since.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.